Status:
COMPLETED
Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients
Lead Sponsor:
JW Pharmaceutical
Conditions:
Gout
Hyperuricemia
Eligibility:
MALE
20-70 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia
Eligibility Criteria
Inclusion
- Diagnosed with gout
Exclusion
- Participated in other clinical study within 12 weeks prior to enrollment, and received an investigational product (including placebo)
Key Trial Info
Start Date :
July 24 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2015
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT02290210
Start Date
July 24 2014
End Date
August 31 2015
Last Update
March 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
JW Pharmaceutical
Seoul, Seocho-dong, South Korea, 137-864